Karyopharm announces fda approval of xpovio® (selinexor) as a treatment for patients with multiple myeloma after at least one prior therapy

Newton, mass., dec. 18, 2020 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the u.s. food and drug administration (fda) has approved xpovio® (selinexor), the company's...
KPTI Ratings Summary
KPTI Quant Ranking